- Neurocrine Biosciences reported first-quarter revenue of $572.6 million, surpassing estimates of $556.2 million, marking an 11% year-over-year increase.
- Collaboration revenue rose by 41% year-over-year to $8.9 million, exceeding the estimate of $7.17 million.
- Research and Development (R&D) expenses increased by 65% year-over-year to $263.2 million, which was higher than the estimated $221.7 million.
- Selling, General, and Administrative (SG&A) expenses increased by 14% year-over-year to $276.5 million, slightly above the estimate of $269.9 million.
- Adjusted earnings per share (EPS) was 70 cents, compared to $1.20 in the previous year, falling short of the $1.14 estimate.
- For 2025, Neurocrine Bio maintains its forecast for Ingrezza net product sales between $2.50 billion and $2.60 billion, aligning with the $2.54 billion estimate.
- The company also maintains its forecast for R&D expenses between $960 million and $1.01 billion, with an estimate of $988.5 million.
- SG&A expenses are forecasted to remain between $1.11 billion and $1.13 billion, in line with the $1.11 billion estimate.
- First-quarter 2025 net product sales of Ingrezza (valbenazine) were confirmed to be $545 million, with the company reiterating its annual sales guidance.
- Analyst recommendations include 21 buys, 4 holds, and 0 sells.
“`
Neurocrine Biosciences on Smartkarma
Independent analysts on Smartkarma, such as Baptista Research, are providing valuable insights into Neurocrine Biosciences. In a report titled “Neurocrine Biosciences: The CRENESSITY Launch & Expansion As A Significant Growth Opportunity!”, analysts delve into the company’s recent earnings, financial performance, and growth prospects. Despite challenges in the biopharmaceutical landscape, Neurocrine continues to showcase solid performance, especially with its key product INGREZZA for tardive dyskinesia, which has seen record growth.
Another report by Baptista Research, “Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers”, highlights the company’s third-quarter 2024 results and strategic initiatives under CEO Kyle Gano. With a focus on becoming a leading neuroscience organization, Neurocrine’s revenue growth, primarily fueled by the success of INGREZZA, has been significant, reaching $613 million in sales this quarter, marking a 25% year-over-year growth.
A look at Neurocrine Biosciences Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Neurocrine Biosciences, Inc. is a company dedicated to finding solutions for various diseases affecting the brain. With a strong focus on neuropsychiatric, neuroinflammatory, and neurodegenerative conditions, the company is working on developing treatments for a wide range of issues including anxiety, depression, Alzheimer’s disease, insomnia, and more.
When looking at the Smartkarma Smart Scores for Neurocrine Biosciences, the company shows promising signs for long-term growth and resilience. With a high score in Growth and Resilience, indicating strong potential for expansion and the ability to withstand challenges, Neurocrine Biosciences seems well-positioned for the future. While there are areas for improvement in terms of Value and Dividend, the company’s Momentum score also suggests positive movement in the market. Overall, the outlook for Neurocrine Biosciences appears optimistic based on the Smart Scores provided.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
